The current ADHD market has long been saturated with traditional methylphenidate and amphetamine based drugs, with the only innovations being the development of extended release versions. However, the recent launch of Strattera (atomoxetine) has already shattered the traditional approach to drug therapy, opening the door for the uptake of new novel drug therapies.

• Overview of the epidemiology, diagnosis and management of ADHD across the seven major pharmaceutical markets
• Examination of the ADHD pipeline with in-depth clinical and commercial profiles of late-stage candidates, incorporating Datamonitor opinion
• Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2015
• Insight and commentary from qualitative interviews with ADHD opinion leaders in the US and Europe

The current global ADHD market is worth $2.7billion and is expected to reach $3.3billion by 2015, driven primarily by the launch of pipeline drugs and the continued growth of Strattera.

Innovation is key - manufacturers can no longer expect significant returns on standard extended release formulations. The current pipeline offers drugs with novel delivery mechanisms; improved durations of action and anti-abuse profiles, which will help differentiate these pipeline drugs from the current established ADHD therapies.

Although ADHD drugs have demonstrated significant efficacy in improving the three main symptoms of ADHD - inattention, hyperactivity and impulsivity - none have shown efficacy in treating the cognitive deficits of ADHD.

• Understand unmet needs in the ADHD market based on opinion leader comments regarding both currently marketed and pipeline products
• Benchmark key late-stage ADHD compounds against current market leaders
• Assess the global sales forecasts of late-stage pipeline drugs for ADHD and examine their clinical and commercial potential